Compare TRAK & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAK | HUMA |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.2M | 155.4M |
| IPO Year | 1996 | N/A |
| Metric | TRAK | HUMA |
|---|---|---|
| Price | $10.44 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 101.7K | ★ 7.3M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $21,007,076.00 | N/A |
| Revenue This Year | $6.61 | $444.16 |
| Revenue Next Year | $10.04 | $248.39 |
| P/E Ratio | $36.82 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $6.94 | $0.55 |
| 52 Week High | $22.17 | $2.93 |
| Indicator | TRAK | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 68.49 |
| Support Level | $10.03 | $0.89 |
| Resistance Level | $10.64 | $1.72 |
| Average True Range (ATR) | 0.46 | 0.13 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 83.33 | 92.45 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.